Table 2. Modelled average seroprevalence estimates of Toxoplasma gondii in humans, by age group and age at infection, Europe, 2000–2021.
| Regiona | Seroprevalence (%), by age group | Age at infection (years) | |||||
|---|---|---|---|---|---|---|---|
| 0–25 years | 26–50 years | > 50 years | Mean | 10% quantile | Median | 90% quantile | |
| Eastern | 16 | 43 | 68 | 63.96 | 6.74 | 44.34 | 147.28 |
| Northern | 4 | 14 | 27 | 249.95 | 26.33 | 173.25 | 575.53 |
| Southeastern | 13 | 38 | 62 | 77.19 | 8.13 | 53.51 | 177.75 |
| Southwestern | 10 | 30 | 52 | 101.66 | 10.71 | 70.46 | 234.08 |
| UK | 4 | 13 | 26 | 259.07 | 27.30 | 179.58 | 596.54 |
| Western | 15 | 41 | 66 | 68.46 | 7.21 | 47.45 | 157.63 |
| Overall | NA | 136.72 | 14.40 | 94.76 | 314.80 | ||
NA: not applicable; UK: United Kingdom.
a Eastern: Belarus, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Ukraine; Northern: Denmark, Finland, Iceland, Norway, Sweden; Western: Austria, France, Germany, Ireland, Liechtenstein, Luxembourg, the Netherlands, Switzerland; Southeastern: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Greece, Kosovo, Moldova, North Macedonia, Serbia, Slovenia; Southwestern: Andorra, Italy, Malta, Portugal, San Marino, Spain.
A total of 69 studies were included in the analysis (two studies with results for more than one region): eastern (26 studies, 7 countries), northern (4 studies, 4 countries), southeastern (9 studies, 5 countries), southwestern (18 studies, 3 countries), western (11 studies, 5 countries), UK (3 studies).